



500 Kendall Street
Cambridge, MA 02142
Tel 800-745-4447

March 23, 2012

RE: Fabrazyme[®] (agalsidase beta) U.S. Supply Update

Dear Healthcare Provider,

We are writing to provide you with an update on Fabrazyme supply in the U.S. Beginning on March 1 2012, patients in the U.S. returned to full dosing of Fabrazyme (1mg/kg every two weeks). We want to inform you that there is no longer a wait list in the U.S. for new patients to begin treatment with Fabrazyme or for patients wishing to transition to Fabrazyme from other therapies. If you would like information on how to begin a patient on treatment, you may contact Genzyme Care Coordination at 1 (800) 745-4447, Option 3.

The recent approval of our new manufacturing plant in Framingham, MA, enables us to provide full dosing of Fabrazyme in the U.S. We are able to provide full dosing for new patients as well as patients currently receiving Replagal who need to transition to Fabrazyme, upon the request of their treating physician.

As supply in the U.S. returns to more normal levels, Genzyme's focus remains on our global recovery and on the return of all patients to full dosing worldwide. The FDA and EMA approvals of the Framingham manufacturing plant have enabled us to start this process. Outside of the U.S., Genzyme is working through additional Regulatory approvals of our new plant, and has begun the process of returning all patients to normal dosing, which will continue globally throughout the year.

For support regarding insurance and billing issues, infusion agency questions, or additional information about the supply of Fabrazyme, or to give Genzyme your feedback, healthcare providers and patients should contact their Genzyme Case Manager at 1 (800) 745-4447, Option 3 or Genzyme Medical Information at 1 (800) 745-4447, Option 2.

Thank you.

Sincerely,

A handwritten signature in black ink, appearing to read "D. Gruskin".

Daniel Gruskin, MD, Head US Medical Affairs

A handwritten signature in black ink, appearing to read "Stephanie S. Okey".

Stephanie Okey, M.S. Vice President & General Manager
U.S. Genetic Diseases